Greater Philadelphia Life Sciences Series A Rounds: Where Are They Now? (Part 1)

Published on :

Much blood, sweat and tears are spent to advance a concept, pilot or potential therapy to a point where investors are willing to back a company, often pouring millions of dollars into their coffers. Series A funding is crucial to any growing organization as it provides the financial runway to purchase equipment, build facilities, hire talent and invest in R&D and clinical trials. 

XyloCor Makes Significant Progress in Gene Therapy for Cardiovascular Disease

Published on :

XyloCor Therapeutics, based in Wayne, Pa., recently announced its Phase I/II EXACT trial has wrapped the Phase II portion of the study. The trial was evaluating the company’s lead gene therapy candidate XC001 (encoberminogene rezmadenovic) in patients with refractory angina.